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Abstract Carney complex (CNC) is a multiple neoplasia syn-
drome that consists of endocrine (thyroid, pituitary, adrenocor-
tical and gonadal), non-endocrine (myxomas, nevi and other
cutaneous pigmented lesions), and neural (schwannomas) tu-
mors. Primary pigmented nodular adrenocortical disease
(PPNAD) is the most common endocrine manifestation of
CNC and the only inherited form of Cushing syndrome known
to date. In the search of genes responsible for CNC, two chro-
mosomal loci were identi¢ed; one (17q22^24) harbored the gene
encoding the type I-K regulatory subunit (RIK) of protein kinase
A (PKA), PRKAR1A, a critical component of the cAMP sig-
naling pathway. Here we review CNC and the implications of
this discovery for the cAMP and/or PKA’s involvement in hu-
man tumorigenesis.
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1. What is Carney complex (CNC)?
CNC is a multiple neoplasia syndrome [1] (listed in the
Mendelian Inheritance in Man (MIM) catalogue under num-
ber #160980 (see http://www.ncbi.nlm.nih.gov/omim)) [2] fea-
turing cardiac, endocrine, cutaneous and neural tumors, and a
variety of mucocutaneous pigmented lesions [3^9]. CNC is
inherited as an autosomal dominant trait and involves simul-
taneously most of the endocrine glands (pituitary, thyroid,
adrenal cortex, gonads but not the hypoparathyroids or the
pancreas), much like the other multiple endocrine neoplasia
syndromes [8]. CNC also has some similarities to McCune^
Albright syndrome and shares skin abnormalities and some
non-endocrine tumors with the lentiginoses and/or the hamar-
tomatoses, such as Peutz^Jeghers syndrome, in particular, but
also Cowden disease and the Bannayan^Zonana (Bannayan^
Myhre^Smith), Birt^Hogg^Dube¤ and neuro¢bromatosis (NF)
syndromes [7].
2. Epidemiology
Approximately 400 patients with CNC from all races and
with equal distribution between the sexes are listed in the
National Institutes of Health-Mayo Clinic (NIH-MC) registry
[10]. Most of the patients (more than two-thirds) belong to
families in which the disease is inherited in an autosomal
dominant fashion [4]. The number of a¡ected members in
the majority of these families is small : in the NIH-MC regis-
try, the maximum number of a¡ected generations in a family
was ¢ve. CNC is a developmental disorder, occasionally diag-
nosed at birth. Most commonly, however, the disease is diag-
nosed in late adolescence or young adulthood.
Abnormal skin pigmentation may be present at birth and is
the ¢rst manifesting sign of the disease; lentigines, however,
do not assume their characteristic distribution, density and
intensity until around and shortly after puberty. Heart myx-
omas [5,6] or Cushing syndrome due to primary pigmented
adrenocortical disease (PPNAD) are the clinical conditions
with which most CNC patients present [11]. Lentigines and
other pigmented lesions [5,6], acromegaly [12^14], thyroid
nodules [15], gonadal tumors [16,17] and schwannomas
[18,19], and other tumors [20^22] may be present at the time
of diagnosis but are rarely the reason for which most patients
seek medical attention for the ¢rst time.
3. Sites of involvement
Mucocutaneous involvement in CNC is extensive: lentigines
and other pigmented lesions, including blue and other nevi,
and cafe¤-au-lait spots may be present at birth, referred to as
‘birthmarks’; more frequently, however, these lesions develop
in the early childhood years (Fig. 1). The cafe¤-au-lait spots in
CNC are usually smaller and less pigmented than those in
McCune^Albright syndrome; they also tend to fade with
time. Their shape is more reminiscent of the NF syndromes;
however, unlike those of NF, cafe¤-au-lait spots in CNC do
not usually enlarge with time. Depigmented lesions, often
mimicking vetiligo, could be present in patients with CNC.
The skin and the mucosa may also develop myxomas at any
age in patients with CNC; although any site could harbor a
myxoma, characteristic locations include the junctions of the
keratinized and mucosal epithelium (the eyelids, nipples, labia
majora, prepuce). A skin tumor with myxoid elements but
distinct from other lesions and quite characteristic for patients
with CNC is trichofolliculoepithelioma; it is usually found in
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the ear canal and is reminiscent of similar tumors of the hair
follicle in Cowden disease and Birt^Hogg^Dube¤ syndrome.
After the mucocutaneous sites, the heart and the breast are
next the two most common locations for myxomas in CNC.
Myxomas may occur everywhere in the heart of patients with
CNC, at any age and without any gender predilection, unlike
the common sporadic tumors that occur mostly in the left
atrium, and in older females. Breast myxomatosis is extensive
and often associated with yet another benign tumor of the
mammary gland: ductal adenoma [20,21]. The adrenal cortex
in almost all patients with CNC has histologic changes con-
sistent with PPNAD [11], whereas ovarian cysts and large cell,
calcifying Sertoli cell tumors (LCCSCT) are present in the
gonads. Non-functioning nodules and occasionally follicular
or papillary carcinoma may be present in the thyroid. All of
the these tumors are easily detectable by ultrasonography:
LCCSCT appear as microcalci¢cations, and multiple hypo-
echoic lesions are seen in the ovaries and the thyroid, often
within the ¢rst two decades of life. Several patients with CNC
develop a unique tumor of the peripheral nervous system,
psamommatous melanotic schwannoma (PMS), which is often
multicentric and may be found in the retroperitoneal space,
along the spine, the mediastinum and the pelvis. PMS is one
of the few tumors associated with CNC that may assume an
aggressive clinical behavior and metastasize to distant sites,
primarily the lungs and the central nervous system (CNS)
but also the heart, stomach and liver.
4. Clinical features
At least two of the classic manifestations of CNC need to
be present to make the diagnosis of CNC (Table 1) [10]. Most
patients with CNC present spotty mucocutaneous pigmenta-
tion on the vermilion border of the lips, the saddle of the
Fig. 1. Lentigines in patients with CNC. A girl without mutations of the PRKAR1A gene who has intense pigmentation both around the face
(A) and the mouth (B) (the vermilion border of the lips). Another patient with the complex, and a PRKAR1A mutation, who has minimal pig-
mentation overall but does have signi¢cant pigmentation around the mouth and on the lips (C).
Fig. 2. Serial slices of an adrenal cortex with PPNAD from a patient with CNC. Some pigmented nodules are visible macroscopically.
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nose, the inner and outer canthi and around the eyes, and
elsewhere (in the face, trunk, external genitalia) (Fig. 1), and
one of the two most common types of tumors: myxoma or
PPNAD. Symptoms of heart myxoma are cardiac insu⁄-
ciency, stroke, or those caused by distant embolization (in
the lungs, brain, and the extremities). Skin myxomas resemble
neuro¢bromas clinically and are often misdiagnosed as such
histologically. They often present in the form of simple skin
tags (in the penis, nipple, neck, ¢nger- and toe-tips, the peri-
neal region), or they may grow over several years as tender,
¢xed subcutaneous nodules (almost anywhere in the face,
trunk and extremities, although the most common locations
are in the lower back and gluteal regions). In the ‘classic’
patient with spotty skin pigmentation (in the characteristic
distribution), skin myxoma(s) and symptoms of Cushing syn-
drome (facial plethora, central obesity, striae), the diagnosis
of CNC is easily made. In a patient with suggestive skin
pigmentation but no signs of a heart tumor or typical Cushing
syndrome, echocardiography or biochemical screening by a
dexamethasone stimulation test may reveal a myxoma or
PPNAD, respectively. PPNAD in a patient with CNC may
often have an indolent, atypical presentation, although the
typical macro- and microscopic manifestations are always
there (Fig. 2), independently of the severity of the clinical
disease. Ultrasonography has been used to detect some of
the other tumors associated with the complex: LCCSCT (mul-
ticentric, bilateral microcalci¢cations), Leydig cell and adrenal
rest tumors (these rare tumors, if present, are always found
together with LCCSCT), thyroid nodules and ovarian cysts
(multiple, bilateral, hypoechoic lesions). LCCSCT in CNC,
as in Peutz^Jeghers syndrome, may be hormone-producing,
and cause gynecomastia in prepubertal and peripubertal
boys. Clinically evident acromegaly is a relatively infrequent
manifestation of CNC. However, asymptomatic GH and in-
sulin-like growth factor type 1 (IGF-1) level elevation and
subtle hyperprolactinemia may be present in up to 75% of
the patients. Biochemical acromegaly is often unmasked by
abnormal results of oral glucose tolerance test (oGTT) or
paradoxical responses to thyrotropin-releasing hormone
(TRH) administration. Somatomammotropic hyperplasia, a
putative precursor of GH-producing adenoma, may explain
the insidious and protracted period of establishment of clin-
ical acromegaly in CNC patients. CNC is the only genetic
condition other than the NF syndromes and isolated familial
schwannomatosis that is associated with schwannomas, albeit
a rare and characteristic for the complex type, PMS. If symp-
tomatic, this tumor may a¡ect autonomic or other neurologic
functions, depending on its location, or may cause mass ef-
fects. Metastatic PMS to the lungs or brain may cause ob-
structive lung disease or increased cerebrospinal £uid pressure
and death, respectively. Imaging of the brain, spine, chest,
abdomen (in particular the retroperitoneum), and the pelvis,
may be necessary for the detection of PMS, if there are sug-
gestive symptoms. The most recently described tumor associ-
ated with the complex is osteochondromyxoma, a rarely
present lesion in young patients with CNC that usually in-
volves the long bones, causes swelling, local in£ammation
and discomfort and often requires surgical excision. Rarely,
a patient may be diagnosed with CNC post mortem, usually
after a fatal embolus or stroke due to a heart myxoma or,
infrequently, due to complications of hypercortisolemia or
metastatic PMS.
5. Genetics
Tumor studies showed extensive genomic instability in
CNC cells, unusual for benign tumors. Linkage analysis in
CNC families showed genetic heterogeneity with at least two
main loci for candidate genes; others are likely to be found in
the future. A chromosome 2 (2p15^16) locus was identi¢ed
¢rst [23], but the gene responsible for CNC in that region
remains unknown. The most closely linked region on chromo-
some 2 centers around locus CA2/D2S123. At the second
locus, on chromosome 17 (17q22^24) [24^26], the PRKAR1A
gene was recently identi¢ed (see below) [27,28].
Table 1
Diagnostic criteria for CNC
Major criteria
1 Spotty skin pigmentation with a typical distribution (buccal
mucosa, lips, conjuctiva and inner or outer canthi, vaginal
and penile mucosa)
2 Myxoma (cutaneous and mucosal)a
3 Cardiac myxomaa
4 Breast myxomatosisa or detection by fat-suppressed
magnetic resonance imaging
5 PPNADa or paradoxical positive response of urinary
glucocorticosteroids to dexamethasone administration during
Liddle’s test
6 Acromegaly due to GH-producing adenomaa
7 LCCSCTa or characteristic calci¢cation on testicular
ultrasonography
8 Thyroid carcinomaa or characteristic multiple, hypoechoic
nodules on thyroid ultrasonography
9 PMSa
10 Blue nevus, epithelioid nevus (multiple)a
11 Breast ductal adenoma (multiple)a
12 Osteochondromyxoma of the bonea
13 First degree relative with established diagnosis of CNC
14 Inactivating mutation of the PRKAR1A gene
Minor criteriab
1 Intense freckling (without darkly pigmented spots or typical
distribution)
2 Blue nevus, usual type (if multiple)
3 Cafe¤-au-lait spots or other ‘birthmarks’
4 Elevated IGF-1 levels, abnormal oGTT, or paradoxical GH




7 History of Cushing syndrome, acromegaly, or sudden death
in extended family
Other conditions that may be seen in patients with CNC but are
not diagnostic of the diseaseb
1 Multiple skin tags and other skin lesions; lipomas
2 Colonic polyps (usually in association with acromegaly)
3 Hyperprolactinemia (usually mild and almost always in
association with clinical or subclinical acromegaly)
4 Single, benign thyroid nodule in a young patient; multiple
thyroid nodules in an older patient (detected by
ultrasonography)
5 Family history of carcinoma, in particular of the thyroid,
colon, pancreas and the ovary; other multiple benign or
malignant tumors
aWith histologic con¢rmation.
bNeither the minor criteria nor the other conditions listed in this ta-
ble may be used for the diagnosis of CNC; so far, only the major
criteria may be used to guide clinical and/or molecular diagnosis.
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5.1. PRKAR1A mutations in CNC
The PRKAR1A gene encodes the regulatory subunit I-K of
the protein kinase A (PKA), the main mediator of cAMP
signaling in mammals. PRKAR1A is the most abundant
type I subunit of the PKA tetramer. The predominant type
of PKA isoform in a cell depends on the di¡erentiation and
proliferation stage; hence cellular PKA responses to cAMP
can di¡er signi¢cantly depending on the type of the tetramer.
The expression of PRKAR1A has shown to be altered in sev-
eral sporadically occurring tumors and tumor-derived cell
lines from non-CNC patients and was, indeed, a good candi-
date gene for endocrine and non-endocrine tumorigenesis in
CNC. Among the kindreds registered at NIH-MC, about half
carried PRKAR1A mutations, although this percentage may
be higher among patients presenting with PPNAD only. In
almost all mutations the sequence change is predicted to lead
to a premature stop codon. Analysis of mRNA transcripts in
patient lymphocytes showed that mutant mRNAs containing
a premature stop codon were detectable only after treatment
with cycloheximide. In addition, the predicted mtPRKAR1A
Fig. 3. The most frequent, de novo occurring, PRKAR1A mutation in CNC: del c.578TG.
Fig. 4. Allelic loss of a PRKAR1A-containing probe in a cell from a pituitary tumor from a patient with CNC and a PRKAR1A germline mu-
tation.
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protein products were absent in these cells. The most frequent
PRKAR1A mutation in CNC is a deletion in exon 4B that
results in a frameshift, 578delTG (Fig. 3); other frequent mu-
tations are present in exons 2 and 6. Nonsense-mediated de-
cay, in which the cells degrade the mRNA containing a del-
eterious, premature stop codon mutation prior to its
translation, is apparently responsible for destruction of the
abnormal mRNA in mutant PRKAR1A-carrying cells [27,
28].
Preliminary data suggested that, in CNC, PRKAR1A func-
tions as a tumor suppressor gene: tumors from CNC showed
LOH of 17q22^24, and the wild-type allele was lost in asso-
ciated tumors (Fig. 4). As a result of NMD of the pathogenic
allele and LOH of the normal allele, the PRKAR1A protein
was simply not present in CNC tumor cells. This loss of the
most important regulatory subunit of the PKA tetramer was
associated with a greater PKA response to cAMP when com-
pared with non-CNC tumors. Additional data indicate that
the loss of PRKAR1A in CNC tumors leads to compensatory
increases in the other PKA subunits, both type I (PRKAR1B)
and type II (PRKAR2A and PRKAR2B) depending on the
tissue, the cell cycle stage, and perhaps numerous other fac-
tors (Fig. 5). This is not unlike the situation in mouse models
in which one of the PKA subunits is knocked out. Thus, it
appears that the increased cAMP response of PKA activity in
CNC tumors is due to the upregulation of other subunits of
the PKA tetramer, type II regulatory subunits, in particular.
Supportive of this notion are not only the existing mouse
models but also data that indicate that even an abnormal
PRKAR1A (not only complete loss) in CNC tumors is asso-
ciated with increased PKA signaling in response to cAMP
(Fig. 5). These most recent experiments with an in vitro con-
struct of the single (so far) PRKAR1A mutation in a CNC
kindred that leads to an expressed and translated product
con¢rmed that increased PKA responses to cAMP underlie
tumorigenesis in this condition [29]. Interestingly, in tumors
from this kindred there was no LOH, indicating that even in
the presence of haplo-insu⁄ciency tumors may form, presum-
ably due to the imbalance between type I and type II PKA in
the a¡ected cells.
6. Conclusion
Although original evidence suggested that PRKAR1A might
be functioning as a tumor suppressor gene, more recently
haplo-insu⁄ciency has also been documented in association
at least with PPNAD [29]. PRKAR1A somatic mutations have
been found in sporadic thyroid tumors [30] and several other
types of neoplasms are currently under investigation in our
and other laboratories.
In conclusion, in this short review, we presented the most
recent ¢ndings on CNC and PPNAD associated with genetic
defects of PRKAR1A, the ¢rst gene of the PKA tetramer even
to be found mutated in human disease. It remains to be seen
how these abnormalities tie with the known e¡ects of cAMP
and PKA on growth and proliferation, and whether, indeed,
in functional studies, PRKAR1A behaves as a tumor suppres-
sor or has a more complicated role in the regulation of other
signaling pathways, the cell cycle or, perhaps, chromosomal
stability.
Fig. 5. Schematic representation of the PKA signaling pathway in normal (A) and CNC (B) cells. After binding of cAMP to the homodimer
of regulatory subunits, PKA is activated. Catalytic subunits are released following conformational changes of the regulatory subunits; phos-
phorylation of cytoplasmatic targets ensues. Often this is translated to simply ‘crosstalking’ with other intracellular signaling pathways (as the
MAPK). In the nucleus, PKA catalytic subunits phosphorylate CREB resulting in activation of DNA transcription of cAMP-responsive ele-
ments (CRE)-containing genes. In a PRKAR1A mutant cell, where there is no or an ine¡ective regulatory subunit type 1A, there is a compen-
sating excess of the other regulatory subunits which may also lead to an increased availability of free catalytic subunits, and perhaps decreased
inhibition of phosphodiesterases and/or other feedback molecules. The net e¡ect of all these changes in CNC cells is an increase in DNA tran-
scription and/or activation of other pathways leading to abnormal growth and proliferation.
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